PATH Intl CTRI Study Guide Clinical Trial
Regulatory Intelligence Complete Practice
Assessment Actual Exam 2026/2027 Complete
Exam-Style Questions with Detailed Rationales |
100% Verified | Pass Guaranteed – A+ Graded
Part I: Regulatory Frameworks & Guidelines (Questions 1–15)
Q1: A sponsor is preparing to submit a clinical trial application in the European Union. Under the Clinical
Trials Regulation (EU) No 536/2014, which system must they use to submit and manage their
application?
A. The EudraVigilance Clinical Trial Module (EVCTM)
B. The Clinical Trials Information System (CTIS)
C. The Clinical Trials Information System (CTIS) [CORRECT]
D. The European Medicines Agency Portal (EMA-P)
Correct Answer: C
Rationale: The best answer is CTIS. This choice is correct because the EU Clinical Trials Regulation (No
536/2014) established the Clinical Trials Information System as the single entry point for submitting,
assessing, and supervising clinical trials across all EU Member States and EEA countries. This replaced
the older national-level submission processes under the previous Clinical Trials Directive.
Q2: During a routine audit, a quality assurance team notices that a trial site in Japan has implemented a
protocol amendment that was approved by the institutional review board but not yet by PMDA. Under
standard Japanese regulatory requirements, which statement best describes the site's position?
A. The site may proceed since IRB approval is sufficient for immediate implementation
B. The site must wait for PMDA approval before implementing the amendment
C. The site must wait for PMDA approval before implementing the amendment [CORRECT]
D. The site may implement if the amendment is classified as "administrative only"
Correct Answer: C
Rationale: This choice is correct because in Japan, PMDA (Pharmaceuticals and Medical Devices Agency)
approval or notification is required before implementing protocol amendments, even if the IRB has
already approved the change. The regulatory authority's review ensures the amendment aligns with
,national safety and efficacy standards, so proceeding without PMDA clearance would violate Japanese
clinical trial regulations.
Q3: A clinical research associate is reviewing ICH guideline documents and needs to identify which
guideline specifically addresses the statistical principles for clinical trials. Which document should she
pull from the file?
A. ICH E6(R2)
B. ICH E8(R1)
C. ICH E9(R1) [CORRECT]
D. ICH E2F
Correct Answer: C
Rationale: The best answer is ICH E9(R1). This choice is correct because ICH E9 and its addendum
specifically cover statistical principles for clinical trials, including design, conduct, analysis, and reporting.
E6 covers GCP, E8 covers general considerations for clinical studies, and E2F is the development safety
update report guideline, so the CRA would naturally reach for E9 when statistical methodology
questions arise.
Q4: A sponsor is designing a global Phase III trial that will run across 12 countries including the United
States, Germany, Japan, and Brazil. They need to ensure the trial meets Good Clinical Practice standards
that are acceptable to all major regulatory authorities. Which document serves as the universally
recognized harmonized standard?
A. The Declaration of Helsinki
B. ICH E6(R2) Good Clinical Practice [CORRECT]
C. FDA 21 CFR Part 312
D. The WHO Operational Guidelines for Ethics Review Committees
Correct Answer: B
Rationale: This choice is correct because ICH E6(R2) Good Clinical Practice is the internationally
harmonized ethical and scientific quality standard for designing, conducting, recording, and reporting
trials that involve human subjects. While FDA regulations and the Declaration of Helsinki are important,
ICH E6 is specifically designed as the cross-border harmonized standard recognized by FDA, EMA, PMDA,
and other ICH member regulators.
Q5: A clinical trial manager is preparing training materials on ICH E8(R1) General Considerations for
Clinical Studies. Which of the following concepts is most central to the E8(R1) revision's approach to trial
design?
A. Fixed protocol designs with no adaptive elements to maintain statistical purity
B. Quality by Design and proportionate, risk-based approaches to trial conduct [CORRECT]
, C. Mandatory on-site monitoring for 100% of data points to ensure compliance
D. Exclusion of patient-reported outcomes from primary endpoint considerations
Correct Answer: B
Rationale: The best answer is Quality by Design and proportionate, risk-based approaches. This choice is
correct because the E8(R1) revision emphasizes building quality into the trial design from the outset
rather than inspecting it in later, using risk proportionality to focus resources where they matter most.
This represents a shift toward more efficient, fit-for-purpose clinical studies rather than one-size-fits-all
intensity.
Q6: An investigator in the United Kingdom is initiating a commercial clinical trial of a new oncology
compound. After Brexit, which regulatory body is responsible for reviewing and authorizing the clinical
trial application in Great Britain?
A. The European Medicines Agency (EMA)
B. The Medicines and Healthcare products Regulatory Agency (MHRA) [CORRECT]
C. The Health Research Authority (HRA) alone
D. The European Commission Directorate-General for Health
Correct Answer: B
Rationale: This choice is correct because following the UK's withdrawal from the EU, the MHRA became
the standalone competent authority for authorizing clinical trials in Great Britain. While the HRA plays
an important role in ethics and governance arrangements, the MHRA holds the statutory responsibility
for regulatory review and authorization of CTAs in the post-Brexit UK framework.
Q7: A quality manager is explaining ICH E6(R2) Section 5.0 to new monitors. This section primarily covers
which functional area of clinical trial management?
A. Investigator qualifications and selection criteria
B. Quality management and the sponsor's responsibilities for trial management [CORRECT]
C. Informed consent procedures for vulnerable populations
D. Statistical analysis plan development and interim analyses
Correct Answer: B
Rationale: This choice is correct because Section 5.0 of ICH E6(R2) addresses the sponsor's quality
management responsibilities, including quality assurance, quality control, and the overall management
of trial-related activities. Monitors need to understand this section because it frames how sponsors
should oversee sites, manage vendors, and ensure the trial meets its quality objectives from start to
finish.
Regulatory Intelligence Complete Practice
Assessment Actual Exam 2026/2027 Complete
Exam-Style Questions with Detailed Rationales |
100% Verified | Pass Guaranteed – A+ Graded
Part I: Regulatory Frameworks & Guidelines (Questions 1–15)
Q1: A sponsor is preparing to submit a clinical trial application in the European Union. Under the Clinical
Trials Regulation (EU) No 536/2014, which system must they use to submit and manage their
application?
A. The EudraVigilance Clinical Trial Module (EVCTM)
B. The Clinical Trials Information System (CTIS)
C. The Clinical Trials Information System (CTIS) [CORRECT]
D. The European Medicines Agency Portal (EMA-P)
Correct Answer: C
Rationale: The best answer is CTIS. This choice is correct because the EU Clinical Trials Regulation (No
536/2014) established the Clinical Trials Information System as the single entry point for submitting,
assessing, and supervising clinical trials across all EU Member States and EEA countries. This replaced
the older national-level submission processes under the previous Clinical Trials Directive.
Q2: During a routine audit, a quality assurance team notices that a trial site in Japan has implemented a
protocol amendment that was approved by the institutional review board but not yet by PMDA. Under
standard Japanese regulatory requirements, which statement best describes the site's position?
A. The site may proceed since IRB approval is sufficient for immediate implementation
B. The site must wait for PMDA approval before implementing the amendment
C. The site must wait for PMDA approval before implementing the amendment [CORRECT]
D. The site may implement if the amendment is classified as "administrative only"
Correct Answer: C
Rationale: This choice is correct because in Japan, PMDA (Pharmaceuticals and Medical Devices Agency)
approval or notification is required before implementing protocol amendments, even if the IRB has
already approved the change. The regulatory authority's review ensures the amendment aligns with
,national safety and efficacy standards, so proceeding without PMDA clearance would violate Japanese
clinical trial regulations.
Q3: A clinical research associate is reviewing ICH guideline documents and needs to identify which
guideline specifically addresses the statistical principles for clinical trials. Which document should she
pull from the file?
A. ICH E6(R2)
B. ICH E8(R1)
C. ICH E9(R1) [CORRECT]
D. ICH E2F
Correct Answer: C
Rationale: The best answer is ICH E9(R1). This choice is correct because ICH E9 and its addendum
specifically cover statistical principles for clinical trials, including design, conduct, analysis, and reporting.
E6 covers GCP, E8 covers general considerations for clinical studies, and E2F is the development safety
update report guideline, so the CRA would naturally reach for E9 when statistical methodology
questions arise.
Q4: A sponsor is designing a global Phase III trial that will run across 12 countries including the United
States, Germany, Japan, and Brazil. They need to ensure the trial meets Good Clinical Practice standards
that are acceptable to all major regulatory authorities. Which document serves as the universally
recognized harmonized standard?
A. The Declaration of Helsinki
B. ICH E6(R2) Good Clinical Practice [CORRECT]
C. FDA 21 CFR Part 312
D. The WHO Operational Guidelines for Ethics Review Committees
Correct Answer: B
Rationale: This choice is correct because ICH E6(R2) Good Clinical Practice is the internationally
harmonized ethical and scientific quality standard for designing, conducting, recording, and reporting
trials that involve human subjects. While FDA regulations and the Declaration of Helsinki are important,
ICH E6 is specifically designed as the cross-border harmonized standard recognized by FDA, EMA, PMDA,
and other ICH member regulators.
Q5: A clinical trial manager is preparing training materials on ICH E8(R1) General Considerations for
Clinical Studies. Which of the following concepts is most central to the E8(R1) revision's approach to trial
design?
A. Fixed protocol designs with no adaptive elements to maintain statistical purity
B. Quality by Design and proportionate, risk-based approaches to trial conduct [CORRECT]
, C. Mandatory on-site monitoring for 100% of data points to ensure compliance
D. Exclusion of patient-reported outcomes from primary endpoint considerations
Correct Answer: B
Rationale: The best answer is Quality by Design and proportionate, risk-based approaches. This choice is
correct because the E8(R1) revision emphasizes building quality into the trial design from the outset
rather than inspecting it in later, using risk proportionality to focus resources where they matter most.
This represents a shift toward more efficient, fit-for-purpose clinical studies rather than one-size-fits-all
intensity.
Q6: An investigator in the United Kingdom is initiating a commercial clinical trial of a new oncology
compound. After Brexit, which regulatory body is responsible for reviewing and authorizing the clinical
trial application in Great Britain?
A. The European Medicines Agency (EMA)
B. The Medicines and Healthcare products Regulatory Agency (MHRA) [CORRECT]
C. The Health Research Authority (HRA) alone
D. The European Commission Directorate-General for Health
Correct Answer: B
Rationale: This choice is correct because following the UK's withdrawal from the EU, the MHRA became
the standalone competent authority for authorizing clinical trials in Great Britain. While the HRA plays
an important role in ethics and governance arrangements, the MHRA holds the statutory responsibility
for regulatory review and authorization of CTAs in the post-Brexit UK framework.
Q7: A quality manager is explaining ICH E6(R2) Section 5.0 to new monitors. This section primarily covers
which functional area of clinical trial management?
A. Investigator qualifications and selection criteria
B. Quality management and the sponsor's responsibilities for trial management [CORRECT]
C. Informed consent procedures for vulnerable populations
D. Statistical analysis plan development and interim analyses
Correct Answer: B
Rationale: This choice is correct because Section 5.0 of ICH E6(R2) addresses the sponsor's quality
management responsibilities, including quality assurance, quality control, and the overall management
of trial-related activities. Monitors need to understand this section because it frames how sponsors
should oversee sites, manage vendors, and ensure the trial meets its quality objectives from start to
finish.
